Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith Investors Presentation of the Company. The presentation ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Veerhealth Care Ltd filed its investors presentation with BSE, highlighting its pivot from a leasing company (1992) to an Ayurvedic oral care, skincare, and personal care manufacturer with the Ayuveer brand. The company received USFDA approval in June 2025 for Drug (OTC) exports, positioning it among few small-cap Indian firms with a USFDA-cleared plant. It has executed 3 export shipments to the US (targeting 4–5 per month), secured a ₹0.74 crore oral care export order and a ₹0.48 crore skincare/facecare order, and is in talks with a major Russian group for entry into Russia. FY26 revenue is guided at ₹35–40 crore with 10% PAT margin, supported by a recently onboarded leading FMCG client from a 125-year-old business group and an ₹8 crore rights issue at ₹25/share to fund a ₹33 crore expansion.
Positive for shareholders — USFDA clearance unlocks high-margin export markets, the rights issue funds capacity expansion, and FY26 guidance plus multi-year revenue projections (up to ~₹97 crore) signal aggressive growth. Near-term stock reaction could hinge on execution of export orders and successful rights issue subscription.